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Oral iloprost as a treatment for Raynaud's
syndrome: a double blind multicentre placebo
controlled study
J J F Belch, H A Capell, E D Cooke, J D T Kirby, C S Lau, R Madhok, E Murphy,
M Steinberg
Abstract
Objective-To compare the efficacy,
tolerance and safety of 50-150 ,ug orally
administered iloprost given twice a day
versus placebo in patients with Raynaud's
syndrome.
Methods-The study was multicentre
(n = 3), double blind and placebo con-
trolled. Sixty three patients who had eight
or more vasospastic attacks per week were
enrolled. After a one week run-in period,
all patients received either iloprost or
placebo treatment to a maximum tolerated
dose of 150 pg twice a day for 10 days.
Diary cards assessed the duration and
severity of the vasospastic attacks. Side
effects were monitored by direct ques-
tioning. A global assessment of treatment
efficacy was made by the patient at the end
oftreatment and two weeks later.
Results-Patient opinion tended to favour
iloprost at the end of the 10 day treatment
phase (p = 0.09) and this was significant at
day 24 (the follow up visit) (p = 0.011).
Although the duration and severity of
attacks tended to decrease in the iloprost
treated group, these results tended not to
reach statistical significance (for severity
p = 0'06 at end of treatment, p = 0-09 on
day 24).
Conclusion-Iloprost administered intra-
venously has been shown to be of benefit
in the treatment of the Raynaud's syn-
drome associated with systemic sclerosis,
but this route of administration is
inconvenient. This study evaluated the use
of iloprost administered orally to patients
with Raynaud's syndrome. Patient docu-
mented improvement was significantly
improved by iloprost. Diary card analysis
showed a trend in favour of iloprost, but
these results did not reach statistical
significance.
(Ann Rheum Dis 1995; 54: 197-200)
Raynaud's phenomenon is characterised by
episodic digital ischaemia provoked by cold
and emotion.' It may be idiopathic, Raynaud's
disease, or associated with a wide variety of
other conditions, particularly the connective
tissue disorders.2 This secondary form,
Raynaud's syndrome (RS), is a debilitating
condition which can seriously interfere with the
sufferer's quality of life. Progression to digital
ulceration and even gangrene can occur, which
may lead to loss of the digits.
Treatment of RS can be difficult and no
completely satisfactory approach has been
developed. Vasodilatory therapy has been
superseded by the use of calcium channel
antagonists such as nifedipine;3 although these
can be very useful they may have troublesome
side effects and are ineffective in severely
affected patients.4 Several studies have shown
that prostacyclin (PGI2), a potent vasodilator
antiplatelet agent, can reduce the severity and
frequency of Raynaud's attacks and that these
effects are prolonged for several weeks after the
infusion.5 6 PGI2 is chemically unstable, how-
ever, and has a half-life of2-3 minutes, and this
has limited its clinical use. Iloprost (Schering
Chemicals Ltd) is a chemically stable PGI2
analogue and thus has advantages because of
its relative ease of use. It has been shown to
be effective in the treatment of RS when
given intravenously,7 8 and is equipotent with
nifedipine.4 It appears to be effective against
vasospasm even when given in low dose,8 and
may produce significant healing of digital
ulcers.9 Despite this, it still remains a second
choice treatment because of the need for intra-
venous administration.
A slow release orally active preparation of
iloprost is now available and the aim of the
study was to evaluate the safety, tolerance, and
efficacy of orally administered iloprost in
patients with RS secondary to systemic
sclerosis (SSc). The study was multicentre,
placebo controlled and double blind.
Patients and methods
Three centres participated in the study
(Dundee, Glasgow, and London). All centres
followed identical core protocols so that a
meta-analysis of the clinical and safety data
could be made. Sixty three patients fulfilled
enrolment criteria of the study. All had RS
secondary to SSc. RS was defined as inter-
mittent attacks ofblanching and cyanosis of the
digits precipitated by exposure to cold or
emotion, and patients were required to have at
least eight attacks per week to be included in
the study. SSc was diagnosed by the presence
of either proximal scleroderma or two of the
following: sclerodactyly, digital pitting or loss
of pad, bilateral basilar pulmonary fibrosis, and
abnormal nailfold capillaries assessed by
capillaroscopy. The American Rheumatologists'
University Department
ofMedicine,
Ninewells Hospital and
Medical School,
Dundee DD1 9SY,
United Kingdom
J J F Belch
C S Lau
Centre for Rheumatic
Diseases,
Royal Infirmary,
Glasgow G4 OSF,
United Kingdom
H A Capell
R Madhok
E Murphy
Thermographic and
Blood Flow Unit,
Department ofMedical
Electronics,
St Bartholomews
Hospital,
London ECIA 7BE,
United Kingdom
E D Cooke
M Steinberg
Department of
Dermatology
JD T Kirby
Correspondence to:
Dr Belch.
Accepted for publication
12 October 1994
197
Belch, Capell, Cooke, et al
Association criteria were not used for enrol-
ment into this study as patients fulfilling these
have severe disease, often with no vasodilator
reserve, and were felt to be less likely to
respond to the effects of iloprost. All female
patients (n = 58) of child bearing potential
were required to have a negative pregnancy test
before inclusion and to be taking adequate
contraceptive measures. All patients gave
informed written consent and ethical per-
mission for the study was obtained from
the regional ethics committees of all three
centres.
After a washout period of two weeks, during
which no medication for relief of Raynaud's
symptomatology was taken, patients entered
the study. Diary cards were issued and the
patients asked to record, on a daily basis, the
duration of their Raynaud's attacks in minutes,
whether the attack was mild, moderate or
severe, and whether it was painful or not.
These were completed for a seven day run-in
period to ensure that at least eight attacks per
week were documented. If an error in com-
pletion was detected, this seven day run-in
period was repeated. Diary card docu-
mentation continued throughout the study
period to day 24.
Medication was issued after this run-in
period and continued for 10 days. The 10 day
limit on treatment duration is a standard
limitation imposed by the regulatory
authorities on introduction of a novel com-
pound into a patient population. The patients
were formally assessed at the start of the 10 day
treatment period, at day 3, day 10, and two
weeks after the cessation of treatment at day
24. All were inpatients for the first three days
and two nights of the study so that side effects
could be monitored and blood pressure and
pulse rate measured. Blood was taken for
routine haematology and biochemistry (urine
and electrolytes, liver function tests) on day 0
and day 10. A pregnancy test was repeated in
females of child bearing potential on day 10
and also on this day the patient's opinion as to
treatment efficacy was sought. They were
asked if the condition had improved, not
changed, or worsened compared with before
treatment. The study was conducted between
January and April and all patients were asked
to continue with their usual lifestyle including,
for example, use of handwarmers or electric
gloves.
STUDY MEDICATION AND ADMINISTRATION
Iloprost was supplied by Schering Chemicals
Ltd as capsules of 50 jig. Matching placebo
capsules were also provided. The study medi-
Table 1 Comparability ofgroups
Placebo Iloprost
No of patients 31 32
Sex: Male/Female 3/28 2/30
Age (yr) 49 (44-54) 52 (47-57)
Total duration of attacks (min) 809 (549-1070) 918 (380-1456)
Total number of attacks/week 22 (17-27) 24 (18-30)
Number of painful attacks as a proportion of all attacks 0 5 (0 3-06) 0 5 (0 3-06)
Average severity of attacks on scale 0-3 1-9 (1-6-2-1) 1 9 (1-7-2-2)
Values are mean (range) except for median age (range).
cation was administered twice a day either at
08:00 and 14:00, or at 14:00 and 20:00. On
the first day of treatment patients took one
capsule twice, on the second day two capsules
twice, and on the third day three capsules
twice, corresponding to 50-150 ,ug twice a day
or placebo. The greatest tolerated dose was
used for the remaining seven days of treatment.
Patients were allocated to receive either
iloprost or placebo according to separate
computer generated randomisation lists for all
three centres.
STATISTICAL ANALYSES
The data were analysed using either the Mann-
Whitney U test or the independent t test,
depending on the distribution of the data for
continuous variables. The x2 test was used for
comparing categorical data between treatment
groups. For analysis of the duration of
Raynaud's attacks a percentage change from
baseline was used. p < 0-05 was considered
statistically significant.
Results
Table 1 shows that the two groups of patients
were comparable in terms of age, gender, and
Raynaud's attacks. Additionally, there were six
smokers in the placebo group and nine smokers
who received iloprost. Table 2 shows drug
therapy for RS before the washout period; all
medications were stopped before this two week
period. Data from all 63 patients were available
for the analysis of tolerance and safety data.
Fifty three patients were included in the
analysis of the efficacy of the drug; the 10
patients (seven placebo, three iloprost) excluded
from this analysis failed to complete their diary
cards correctly during the treatment phase of
the study. Four patients (one placebo, three
iloprost) withdrawn during the study had all
their available data considered in the analyses;
the three iloprost patients were withdrawn
because of side effects and the placebo patient
because of intercurrent illness.
GLOBAL OPINION
The patients' opinions of treatment are shown
in table 2 and in the figure. In the placebo
group almost 60% of the patients felt that the
symptoms were unchanged or worse after two
weeks follow up (day 24). In contrast, more
than 60% of the patients who received iloprost
felt their condition was improved. The differ-
ence between the treatments approached
statistical significance (p = 0-09) at the end
of treatment (day 10) and was statistically
Table 2 Raynaud's syndrome medication taken in the 14
days before enrolment into the washout phase
Placebo Iloprost
Nifedipine 8 4
Diltiazem 2
Amlodipine 1
Oxypentifyllin - 1
Essential fatty acids 2 5
Total 13 10
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Patients' opinion of treatment with placebo (U) or iloprost (3 ). Abs = Absent. Difference between treatments almost
significant (p = 0 09) at the end of treatment and significant (p = 0 011) atfollow up.
significant at the follow up visit (day 24)
(p = O-Oll).
DURATION AND SEVERITY OF RAYNAUD'S
ATACKS
Table 3 shows the percentage change from
baseline in the total duration of Raynaud's
attacks per week. A greater reduction in mean
total duration of attacks was seen in the
iloprost group compared with placebo, but the
difference did not reach statistical significance.
The severity of Raynaud's attacks was
assessed by calculating the percentage change
in the proportion of painful attacks and the
change in average severity of the attacks using
the scale: 0 = none; 1 = mild; 2 = moderate;
3 = severe (table 4). Iloprost treatment tended
to cause a greater decrease in the number of
painful attacks and a greater decrease in the
severity of the attacks than placebo. At the
end of treatment (day 10) the difference in
Table 3 Total duration ofRaynaud's attacks: changefrom one week run-in baseline used
to compare the duration of attacks per week
Change in duration (%o)
Placebo Iloprost
End of treatment
(week ending on day 10) -24 (-43 to -4) -40 (-57 to -23)
Follow up
During 1st week after treatment -33 (-50 to -16) -11 (-45 to -23)
During 2nd week after treatment -25 (-44 to -5) -25 (-57 to -8)
Values are mean (95% confidence interval). Negative sign indicates decrease from baseline.
average severity of attacks between the groups
just failed to reach statistical significance
(p = 0O06); it again approached significance at
the end of the follow up period (day 24)
(p = 0 09).
ADVERSE EVENTS
There were no serious adverse reactions or
events as defined by the protocol. However,
three patients in the iloprost group suffered
adverse events that caused their withdrawal
from the treatment phase of the study (one had
severe headache, one had headache with
nausea, and one had headache with flushing).
During the three day inpatient phase a large
number of minor adverse reactions were
reported, the most common being headache,
flushing, and nausea. Thirty one of 32 patients
(97%) receiving iloprost and 19 of 31 of
placebo patients (61%) reported one or more
events during the treatment period (p < 0 002):
50% were classified as mild, 32% as moderate,
and 18% severe. This high instance of side
effects obliged the majority of patients to
decrease their dose. The largest dose of three
capsules twice daily was taken by 41% of the
iloprost patients; 18% took the medium dose
of two capsules twice daily and 41% chose to
return to the smallest dose, of one capsule
twice daily. At the selected doses all patients,
except the three documented above, were able
to continue with the medication.
Table 4 Pain and severity ofRaynaud's attacks: changefrom baseline used to compare the pain and severity of attacks per
week
Painful attacks Seventy
Placebo Iloprost Placebo Iloprost
End of treatment
(week ending on day 10) -23 (-50 to 4) 1 (-25 to 27) -1 (-7 to 6) 6 (-12 to -1)
Follow up
During 1st week after treatment 12 (-75 to 98) -9 (-30 to 11) -1 (-11 to 9) -5 (-13 to 3)
During 2nd week after treatment -7 (-60 to 5) -27 (-53 to -1) 0 (-9 to 9) -9 (-18 to -0)
Values are mean (95% confidence interval). Negative sign indicates decrease from baseline.
cn
CL
0.
0)
CD
a1)0~
199
Belch, Capell, Cooke, et al
Discussion
The pathophysiology of Raynaud's phenom-
enon is not yet completely understood but
is known to include contributions from
abnormal neurogenic,'0 blood and blood vessel
wall," and immunological and inflammatory
responses.'2 13 The discovery that PGI2,
produced by the vascular endothelium, is a
potent vasodilator and inhibitor of platelet
aggregation led to interest in the role of
prostanoids in the treatment of RS. Such
theoretical considerations were later supported
by the finding of the anti-white'4 and anti-red'5
blood cell and fibrinolytic activities'6 of prosta-
cylin-all effects which might be expected to
be useful in RS. Intravenous prostaglandins do
appear to produce some benefit,6 7 but they can
be difficult to use and are understandably less
popular with patients than oral medications.
Human volunteer studies with a new formu-
lation of iloprost suitable for oral testing
showed that, with the slow release preparation,
80% of the active substance was absorbed in
the first hour, with a time to maximum plasma
concentrations between 60 and 90 minutes.
After a dose of 150 pg, therapeutic plasma
concentrations were obtained for a period of
3-3 (SD 1.0) hours.
The present study was undertaken to
investigate the efficacy, safety, and tolerance of
the drug in RS patients. Although during treat-
ment the reduction in duration of Raynaud's
attacks was greater in the iloprost group, there
were no statistically significant effects. The
diary card data demonstrated a high placebo
response of 25-30% for this variable. Further-
more, the wide 95% confidence intervals seen
in table 3 indicated a high variability of the
data-a feature often seen with the duration of
attacks in RS. This would have necessitated a
change of 60% from baseline in the iloprost
group to achieve statistical significance. Con-
versely, the diary card data demonstrated a
near significant result for iloprost for the
severity of Raynaud's attacks, with these data
showing less variability. This result is
supported by the data obtained from the
patients' opinions of improvement: the pro-
portion of patients judging their symptoms to
be improved was greater in the iloprost group.
This difference approached significance at
the end of treatment and was statistically
significant at the two week follow up visit when
the placebo effect in the control group had
become attenuated.
Side effects were as expected and were
related to the pharmacological properties of
iloprost.'7 Despite the number of reported side
effects, only three patients felt them to be
intolerable and withdrew from the treatment
phase. The other patients reduced their drug
dosage until the side effects were minimised.
Forty percent of patients tolerated the
maximum dose, whereas 60% did not. An
increase in the maximum dose cannot there-
fore be suggested in an effort to achieve a
greater clinical response. The titration of the
dose over three days to a maximum of 150 jig
twice daily or best tolerated dose is probably
still the best option. The addition of a three
times a day dosage schedule for the smallest
dose (50 ,ug) might improve the response rate
without significantly decreasing tolerance.
In conclusion, iloprost caused a greater
reduction in the severity of the attacks and the
patients' opinion was also in favour of iloprost
over placebo. The effects of iloprost on the
total duration of Raynaud's attacks were
greater than placebo, but did not reach
statistical significance; the high placebo
response rate and variability of data probably
contributed to this. Furthermore, although this
was one of the largest therapeutic studies of RS
in SSc, the relatively small numbers may also
have led to a type 2 error. Future studies to
investigate this compound further should
include larger numbers of patients and a three
times a day dosage of 50 ,ug.
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